ChenLSunSGaoYRanX. Global mortality of diabetic foot ulcer: A systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023;25(1):36–45.
2.
ArmstrongDGSwerdlowMAArmstrongAAConteMSPadulaWVBusSA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020;13(1):16.
3.
WangXYuanCXXuBYuZ. Diabetic foot ulcers: Classification, risk factors and management. World J Diabetes. 2022;13(12):1049–1065.
4.
SteenOGoldenbergRM. The role of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Can J Diabetes. 2017;41(5):517–523.
5.
NealBPerkovicVMahaffeyKW, et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
6.
ZinmanBWannerCLachinJM, et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
7.
WiviottSDRazIBonacaMP, et al.Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
8.
KlugerAYTecsonKMLeeAY, et al.Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18(1):99.
9.
MatthewsDRLiQPerkovicV, et al.Effects of canagliflozin on amputation risk in type 2 diabetes: The CANVAS program. Diabetologia. 2019;62(6):926–938.
10.
KhouriCCracowskiJLRoustitM. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?Diabetes Obes Metab. 2018;20(6):1531–1534.
11.
PerkovicVJardineMJNealB, et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
12.
LinCZhuXCaiX, et al.SGLT2 Inhibitors and lower limb complications: An updated meta-analysis. Cardiovasc Diabetol. 2021;20(1):91.
13.
QiuMDingLLZhangMZhouHR. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diab Vasc Dis Res. 2021;18(2):14791641211011016.
14.
SeeRMTeoYNTeoYH, et al.Effects of sodium-glucose cotransporter 2 on amputation events: A systematic review and meta-analysis of randomized-controlled trials. Pharmacology. 2022;107(3-4):123–130.
15.
LiCXLiuTTZhangQ, et al.Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: A meta-analysis of cohort studies. Front Pharmacol. 2023;14:1275060.
16.
HodgsonAGilliesCLHightonP, et al.Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort studies. Diabetes Obes Metab. 2024;26(6):2487–2491.
17.
YuanZDeFalcoFJRyanPB, et al.Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab. 2018;20(3):582–589.
18.
UdellJAYuanZRushTSicignanoNMGalitzMRosenthalN. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: Results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018;137(14):1450–1459.
19.
DumortierCAhoGleleSRoulandA, et al.Effects of sodium-glucose cotransporter 2 inhibitor use on mortality, amputation, and healing in patients with diabetic foot ulcer. Diabetes Care. 2026;49(4):674–681.
20.
SchaperNCvan NettenJJApelqvistJ, et al.Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes Metab Res Rev. 2024;40(3):e3657.
21.
PapadokostakiERizosETigasSLiberopoulosEN. Canagliflozin and amputation risk: Evidence so far. Int J Low Extrem Wounds. 2020;19(1):21–26.
22.
KatsikiNDimitriadisGHahalisG, et al.Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: An expert panel overview of the evidence. Metabolism. 2019;96:92–100.
23.
BonacaMPCatarigAMHoulindK, et al.Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580–1593.
24.
PantazopoulosDPapachristouSVasPRJPapanasN. Walking further with GLP-1RAs: Lessons from the STRIDE trial. Int J Low Extrem Wounds. 2026;25(1):5–7.
25.
PantazopoulosDPapanasN. Do dipeptidyl peptidase-4 inhibitors promote healing of diabetic foot ulcers? Insights from a recent meta-analysis. Int J Low Extrem Wounds. 2026:15347346261419303. Online ahead of print.
26.
AmiratAAlmasalmaMElshazlyMAElhosaryMMYounesM. Efficacy of dipeptidyl peptidase-4 inhibitors in diabetic foot ulcer healing: A meta-analysis of randomized clinical trials. Int J Low Extrem Wounds. 2026:15347346251413943. Online ahead of print.
27.
PantazopoulosDGouveriEPopovicDSPapanasN. Continuous glucose monitoring and diabetic foot ulcers: Is it time to walk in range? A brief narrative review. Int J Low Extrem Wounds. 2026:15347346261415723. Online ahead of print.
28.
GouveriEPapanasN.The emerging role of continuous glucose monitoring in the management of diabetic peripheral neuropathy: A narrative review. Diabetes Ther. 2022;13(5):931–952.
